Emergent BioSolutions Inc. (NYSE:EBS) Short Interest Up 6.6% in June

Emergent BioSolutions Inc. (NYSE:EBS) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 6,330,000 shares, an increase of 6.6% from the May 31st total of 5,940,000 shares. Based on an average daily trading volume, of 4,550,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 12.6% of the shares of the company are sold short.

Insider Buying and Selling

In other Emergent BioSolutions news, Director Kathryn C. Zoon sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the sale, the director now directly owns 54,482 shares of the company’s stock, valued at $332,885.02. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 12,919 shares of company stock valued at $75,831. 1.20% of the stock is owned by insiders.

Institutional Trading of Emergent BioSolutions

Several institutional investors have recently made changes to their positions in the business. Laurion Capital Management LP purchased a new position in Emergent BioSolutions in the 3rd quarter worth approximately $37,000. Avidian Wealth Solutions LLC purchased a new position in shares of Emergent BioSolutions in the first quarter worth $33,000. Tidal Investments LLC bought a new position in shares of Emergent BioSolutions during the first quarter worth $34,000. CoreCap Advisors LLC purchased a new position in Emergent BioSolutions during the fourth quarter valued at $33,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Emergent BioSolutions by 52.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,867 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 6,823 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Stock Up 6.2 %

Emergent BioSolutions stock opened at $7.50 on Wednesday. Emergent BioSolutions has a 12-month low of $1.42 and a 12-month high of $8.29. The firm has a 50 day moving average of $5.20 and a 200 day moving average of $3.29. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.08 and a quick ratio of 0.55.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.65) by $4.24. The firm had revenue of $300.40 million during the quarter. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 18.53%. During the same period last year, the company earned ($3.17) earnings per share. On average, analysts expect that Emergent BioSolutions will post -1.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a “buy” rating and issued a $8.00 target price on shares of Emergent BioSolutions in a report on Tuesday.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.